HBL – Hadasit Bio-Holdings Ltd.
(the “Company”)
October 27, 2015
To To
Israel Securities Authority Tel Aviv Stock Exchange Ltd.
www.isa.gov.il www.tase.co.il
Re: Update Regarding Focus of Company Activity and Infrastructure Adaptation
The Company is announcing that D Pharm Ltd., a company traded on the Tel Aviv Stock Exchange in which the Company holds a 5.57% stake (hereinafter: “D Pharm”), filed an immediate report today stating that on October 26, 2015 the D Pharm board of directors resolved that D Pharm would focus its managerial and financial resources on the following activities: (a) development of D Pharm's flagship product, the THR-18, including the performance of Phase IIa clinical trials on patients who suffered an ischemic stroke and are being treated with tPA in conjunction with THR-18; (b) continued cooperation with Jiahgsu Nhwa Pharmaceutical Co. Ltd. in the development of the DP-VPA product intended for treatment of epilepsy and manic depression; and (c) identification of a strategic partner for the further development of D Pharm's products.
Further to the above, the D Pharm board of directors instructed D Pharm management to immediately act to adapt D Pharm's infrastructure (manpower, offices and associated expenses) to the new scope of activity.
D Pharm will provide future updates with regard to actions taken.
For more information concerning D Pharm's report on this matter, see D Pharm's immediate report dated October 27, 2015 (reference number 2015-01-142683).
Sincerely
HBL – Hadasit Bio-Holdings Ltd.
By: Ms. Tamar Kfir, CEO
| 
